Reviewing Syndax Pharmaceuticals (SNDX) and Its Competitors

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Syndax Pharmaceuticals to related companies based on the strength of its profitability, analyst recommendations, dividends, risk, earnings, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of current ratings and price targets for Syndax Pharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syndax Pharmaceuticals 1 0 10 0 2.82
Syndax Pharmaceuticals Competitors 9941 15330 45745 1605 2.54

Syndax Pharmaceuticals currently has a consensus target price of $41.60, suggesting a potential upside of 358.65%. As a group, “Biotechnology” companies have a potential upside of 132.48%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than its peers.

Earnings and Valuation

This table compares Syndax Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Syndax Pharmaceuticals $172.35 million -$285.42 million -3.84
Syndax Pharmaceuticals Competitors $688.58 million $7.69 million -18.51

Syndax Pharmaceuticals’ peers have higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Syndax Pharmaceuticals has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals’ peers have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.

Profitability

This table compares Syndax Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Syndax Pharmaceuticals -72.32% -804.38% -34.93%
Syndax Pharmaceuticals Competitors -12,224.75% -204.85% -31.52%

Summary

Syndax Pharmaceuticals peers beat Syndax Pharmaceuticals on 7 of the 13 factors compared.

About Syndax Pharmaceuticals

(Get Free Report)

Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.